Accelerated Communication

Why Do Most Human Liver Cytosol Preparations Lack Xanthine Oxidase Activity?[S]

John T. Barr, Kanika V. Choughule, Sahadev Nepal, Timothy Wong, Amarjit S. Chaudhry,
Carolyn A. Joswig-Jones, Michael Zientek, Stephen C. Strom, Erin G. Schuetz,
Kenneth E. Thummel, and Jeffrey P. Jones

Department of Chemistry, Washington State University, Pullman, Washington (J.T.B., K.V.C., S.N., C.A.J.-J., J.P.J.); Department of Pharmaceutics, University of Washington, Seattle, Washington (K.E.T., T.W.); Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee (A.S.C., E.G.S.); Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden (S.C.S.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., La Jolla, California (M.Z.)

ABSTRACT

When investigating the potential for xanthine oxidase (XO)-mediated metabolism of a new chemical entity in vitro, selective chemical inhibition experiments are typically used. Most commonly, these inhibition experiments are performed using the inhibitor allopurinol (AP) and commercially prepared human liver cytosol (HLC) as the enzyme source. For reasons detailed herein, it is also a common practice to perfuse livers with solutions containing AP prior to liver harvest. The exposure to AP in HLC preparations could obviously pose a problem for measuring in vitro XO activity. To investigate this potential problem, an HPLC-MS/MS assay was developed to determine whether AP and its primary metabolite, oxypurinol, are retained within the cytosol for livers that were treated with AP during liver harvest. Differences in enzymatic activity for XO and aldehyde oxidase (AO) in human cytosol that can be ascribed to AP exposure were also evaluated. The results confirmed the presence of residual AP (some) and oxypurinol (all) human liver cytosol preparations that had been perfused with an AP-containing solution. In every case where oxypurinol was detected, XO activity was not observed. In contrast, the presence of AP and oxypurinol did not appear to have an impact on AO activity. Pooled HLC that was purchased from a commercial source also contained residual oxypurinol and did not show any XO activity. In the future, it is recommended that each HLC batch is screened for oxypurinol and/or XO activity prior to testing for XO-mediated metabolism of a new chemical entity.

Introduction

Human xanthine oxidase (XO) and aldehyde oxidase (AO) are two closely related molybdoflavoenzymes that share a remarkable degree of amino acid sequence identity, require the same cofactors (Garattini et al., 2003), and appear to share a similar mechanism (Alfaro and Jones, 2008). Despite their similarities, each enzyme is thought to have distinct substrate specificities, with AO being much more promiscuous (Garattini and Terao, 2012). In the field of drug metabolism in particular, AO has burgeoned as an important enzyme primarily for its ability to oxidize a number of azaheterocyle containing drugs (Pryde et al., 2010). A number of drug candidates were also recently discontinued in early clinical studies because of either low bioavailability or toxicity attributed to rapid AO metabolism (Hutzler et al., 2013). In contrast, XO drug substrates have rarely been noted in recent literature. For many years, allopurinol (Elion et al., 1966) and 6-mercaptopurine (Rashidi et al., 2007) have remained the major XO substrates of clinical significance.

To distinguish between XO and AO metabolic activity for a new chemical entity in vitro, selective chemical inhibition experiments are typically used (Hutzler et al., 2013). Most commonly, allopurinol is used to selectively inhibit XO (Panoutsopoulos et al., 2004), and menadione is used to target AO activity (Pryde et al., 2010). Recently, hydralazine has also been suggested as a potent and highly selective AO inhibitor (Strelevitz et al., 2012). These inhibition experiments are most often performed with human liver cytosol (HLC), which appears to be the most common source of this enzyme.

HLC is prepared from donor livers that were harvested using either of two methods. Most commonly, livers are procured from deceased donors via a full hepatectomy in which the entire liver is removed and subsequently processed and separated into microsomal and cytosolic

ABBREVIATIONS: AO, aldehyde oxidase; AP, allopurinol; DACA, *N*-[(2-dimethylamino)ethyl]acridine-4-carboxamide; HLC, human liver cytosol; IS, internal standard; MDL, method detection limit; MRM, multiple reaction monitoring; LC-MS/MS, liquid chromatography tandem mass spectrometry; UW, University of Wisconsin; XO, xanthine oxidase.

fractions. The second procurement method involves live donors in which a partial hepatectomy, or liver resection, is performed. When livers are obtained via full hepatectomy, the livers are typically flushed, or perfused, with a standardized solution prior to being removed. Perfusion is important prior to liver transplantation, in which the solution acts to preserve the liver tissue and protect it from reperfusion injury. Reperfusion injury is a phenomenon that results from oxidative damage that occurs to the tissue when the blood supply returns to the liver after a period of ischemia (Mendes-Braz et al., 2012). Additives in the perfusion solution can mitigate the damage caused by these deleterious oxidative processes. Since the late 1980s, the gold standard perfusion solution has been University of Wisconsin (UW) solution (Mühlbacher et al., 1999; Feng et al., 2007). Despite other alternative solutions, UW solution continues to be the most commonly used preservation solution in liver transplantation surgery (Watson and Dark, 2012). UW solution is principally composed of potassium, lactobionate, and hydroxyethyl starch, but also contains 1 mM of allopurinol (Janssen et al., 2004), which is of primary concern to the present study.

Because of the possibility that livers may be exposed to high amounts of allopurinol (AP) during the harvesting process and the fact that AP is a potent XO inhibitor, the question was raised: does the method of liver harvesting have an impact on in vitro XO enzymatic activity? The goal of this study was to answer the aforementioned question, thereby documenting the presence of residual AP within the cytosol as well any effect of using a solution containing AP in the liver harvesting process on both XO and AO activity. Herein, the activity differences were evaluated in human cytosol prepared from liver tissue harvested in three different ways: full hepatectomy with UW perfusion solution present, full hepatectomy with a perfusion solution not containing AP, and partial hepatectomy (resection).

Materials and Methods

Intact liver tissue from individual donors was obtained from the University of Washington ($n = 10$) and St. Jude Children's Research Hospital ($n = 10$) human liver banks. Both were maintained with complete anonymity of the tissue donor and thus exempt from human subjects research regulations, as determined by the respective Institutional Review Boards and federal regulation. Liver tissue obtained from St. Jude Children's Research Hospital was processed through the St. Jude Liver Resource by the Liver Tissue Procurement and Distribution System (NIH Contract #N01-DK-9-2310) and by the Cooperative Human Tissue Network. Commercial human liver cytosol (pooled from 150 individual donors of mixed gender) was purchased from BD Biosciences (Franklin Lakes, NJ). Allopurinol, oxypurinol, 6-nitroquinazolinedione, 6-mercaptopurine, and 2-methyl-4(3H)-quinazolinone were obtained from Sigma-Aldrich (St. Louis, MO). 6-Thiouricacid and heavy isotope labeled oxypurinol were obtained from Toronto Research Chemicals (Toronto, ON, Canada). N-[(2-Dimethylamino)ethyl]acridine-4-carboxamide (DACA) (Barr and Jones, 2013) and 6-nitroquinazolinone (Alfaro et al., 2009) were synthesized according to previously published methods. DACA-9(10H)-acridone was kindly provided by Dr. William A. Denny from University of Auckland (Auckland, New Zealand). All other reagents used were analytical grade or better.

Preparation of Cytosol from Liver Tissue

For each liver, approximately 0.25–1.6 g tissue was combined with 3.5 ml homogenization buffer (50 mM KPi, 0.25 M sucrose, 1 mM EDTA, pH 7.4) and 18 ceramic beads (2.8 mm; Omni International, Kennesaw, GA) in a 7-ml polypropylene tube. A homogenate was generated using the Omni Bead Ruptor 24 Homogenizer with attached BR-Cryo cooling unit, operated under the following settings: 5.8 m/s, 45 second/cycle, 30-second dwell time, and 2 cycles between -10 to -15°C. The homogenate was transferred to a clean 10-ml polycarbonate centrifuge tube and subjected to $15,000g$ for 30 minutes at 4°C. The resulting supernatant was transferred to a clean ultracentrifuge tube, diluted with homogenization buffer to balance, and centrifuged at $120,000g$ for

70 minutes at 4°C. The cytosol (supernatant) was removed, transferred into 1.5-ml storage tubes, and stored at -80°C.

Enzyme Activity Assays

All assays were performed in 25 mM potassium phosphate buffer, pH 7.4, in a shaking water bath incubator at 37°C. All substrate stocks were made in dimethylsulfoxide and diluted such that the final concentration of dimethylsulfoxide did not exceed 1% v/v. All reactions were stopped by the addition of a solution composed of 1 M formic acid and a known concentration of IS. Incubations were performed as described below and immediately analyzed by LC-MS/MS.

Determination of XO Activity. A final concentration of 1 mg/ml protein was used in all incubations. In the 6-mercaptopurine assay, the incubation was performed for 60 minutes with 100 μM substrate. Activity was quantified by monitoring the formation of the metabolite, 6-thiouric acid. For 6-nitroquinazolinone, the incubation was performed for 10 minutes with 20 μM substrate. Activity was quantified by monitoring the formation of the metabolite 6-nitroquinazolinedione.

Determination of AO Activity. A final protein concentration ranging between 0.15 and 0.66 mg/ml was used. Preliminary experiments showed that product formation was linear with respect to protein concentration within the range used in these activity experiments. The incubation was performed for 10 minutes with 100 μM substrate (DACA). DACA activity was quantified by monitoring the formation of the metabolite DACA acridone.

AO IC_{50} Assays. DACA was used as the probe substrate for AO activity at approximately K_m concentrations (5 μM). Reactions were carried out for 5 minutes using commercially purchased pooled HLC with a final protein concentration of 0.05 mg/ml.

Liver Cytosol Treatment of Allopurinol and Oxypurinol Detection

Human liver cytosol samples were treated with a formic acid solution containing a known amount of 2-methyl-4(3H)-quinazolinone as internal standard, such that the final concentration of formic acid was 200 mM. Samples were vortexed and subsequently frozen at -80°C to induce protein precipitation. Upon thawing, the samples were centrifuged for 10 minutes at 5000 rpm using an Eppendorf 5415D centrifuge. The supernatant was collected and analyzed immediately by HPLC-MS/MS.

HPLC-MS/MS

All samples were detected using an 1100 series high-performance liquid chromatography system (Agilent Technologies, Santa Clara, CA) coupled to an API 4000 tandem mass spectrometry system (Applied Biosystems/MDS Sciex, Foster City, CA) with a turbospray electrospray ionization source. Mobile phases comprised 0.05% formic acid and 0.2% acetic acid in water (A) and 90% acetonitrile, 9.9% water, and 0.1% formic acid (B).

Detection of Allopurinol and Oxypurinol. Chromatography was performed on a Zorbax Eclipse XDB-C8 column (4.6 × 150 mm, 5 μM; Agilent Technologies). With a flow rate of 800 μl/min, the column was equilibrated at initial conditions of 99% mobile phase A for 2.5 minutes. Chromatographic separation was performed using a linear gradient over the next 17.5 minutes to 5% mobile phase A and was held at 5% A for 1 minute. Over the next minute, mobile phase A was ramped back to 99% and then held constant for a re-equilibration time of 3 minutes. The total chromatographic assay time was 25 minutes per sample, and the retention times for allopurinol, oxypurinol, and 2-methyl-4(3H)-quinazolinone (IS) were 4.2, 4.9, and 8.5 minutes, respectively. The MRM m/z transition monitored for allopurinol, oxypurinol, and 2-methyl-4(3H)-quinazolinone (IS) was $137.1 \rightarrow 110.1$, $153.1 \rightarrow 136.1$, and $161.2 \rightarrow 120.1$, respectively. Quantitation was achieved by extrapolating from a standard curve of authentic allopurinol and oxypurinol using a concentration range of 0.06 to 60 μM. The method detection limit for allopurinol and oxypurinol was determined to be 0.027 and 0.025 μM, respectively.

To validate the assay, heavy isotope labeled oxypurinol (oxypurinol-$^{13}C^{15}N_2$) was spiked into each sample and monitored using a MRM transition of $156.1 \rightarrow 139.1$. It was ensured that the retention time for all peaks for oxypurinol matched exactly with the heavy isotope labeled standard. Further validation of analyte recovery and linearity in a complex matrix was also performed. A sample of HLC that contained no detectable amount of AP or oxypurinol was used as a matrix blank for this experiment. Known concentrations of AP and oxypurinol

were added to both buffer and the matrix blank in separate vials, and the measured values were compared (see Supplemental Fig. 2). A total of 7 points was used for allopurinol and 8 points for oxypurinol. The concentration range for each analyte covered the minimum and maximum concentration values for any tested HLC in this study.

Detection of 6-Thiouricacid. Chromatography was performed on a Zorbax Eclipse XDB-C8 column (4.6 × 150 mm, 5 μM; Agilent Technologies). With a flow rate of 800 μl/min, the column was equilibrated at initial conditions of 99% mobile phase A for 3 minutes. Chromatographic separation was performed using a linear gradient over the next 1.5 minutes to 25% mobile phase A and was held at 25% A for 1.5 minutes. Over the next minute, mobile phase A was ramped back to 99% and then held constant for a re-equilibration time of 1 minute. The total chromatographic assay time was 8 minutes per sample, and the retention times for 6-thiouric acid and 3,5-dibromo-4-hydroxybenzoic acid (IS) were 4.3 and 6.8 minutes, respectively. The MRM m/z transitions monitored for 6-thiouric acid and 3,5-dibromo-4-hydroxybenzoic acid (IS) were 183.0 → 140.2 and 294.8 → 251.0, respectively. Quantitation was achieved by extrapolating from a standard curve of authentic 6-thiouric acid using a concentration range of 0.2 to 10 μM. The method detection limit for 6-thiouric acid was determined to be 0.140 μM.

Detection of 6-Nitroquinazolinedione. Chromatography was performed on a Synergi Polar reverse-phase column (30 × 3.0 mm, 4 μm; Phenomenex, Torrance, CA). With a flow rate of 800 μl/min, the column was equilibrated at initial conditions of 95% mobile phase A for 0.3 minutes. Chromatographic separation was performed using a linear gradient over the next 2.2 minutes to 25% mobile phase A and was held at 25% A for 0.5 minutes. Over the next 1.5 minutes, mobile phase A was ramped back to 95% and then held constant for a re-equilibration time of 1 minute. The total chromatographic assay time was 4.5 minutes per sample, and the retention times for 6-nitroquinazolinedione and 2-methyl-4(3H)-quinazolinone (IS) were 1.8 and 1.3 minutes, respectively. The MRM m/z transitions monitored for 6-nitroquinazolinedione and 2-methyl-4(3H)-quinazolinone (IS) were 208.0 → 162.0 and 161.2 → 120.1, respectively. Quantitation was achieved by extrapolating from a standard curve of authentic 6-nitroquinazolinedione using a concentration range of 1 to 25 μM. The method detection limit for 6-nitroquinazolinedione was determined to be 0.85 μM.

Detection of DACA Acridone Metabolite. LC-MS/MS conditions were performed as described previously (Barr and Jones, 2013).

Determination of Method Detection Limit

For calculating MDL, a repeat injection approach was used as described previously (https://www.chem.agilent.com/Library/technicaloverviews/Public/5990-7651EN.pdf; Barr et al., 2013). In short, a concentration of each authentic analyte that produced a signal approximately 5–10 times the noise was chosen. Each standard was injected onto the column a total of 5 times, and the peak areas were determined. The MDL was calculated using the following formula:

$$\text{MDL} = S_{\bar{x}}\, \text{T}_{\alpha}$$

Where $S_{\bar{x}}$ is equal to the standard deviation of the mean for peak area and T_{α} is the value chosen from a t-table for $n = 5$ at a 99% confidence interval.

Results and Discussion

To ascertain any differences between liver harvesting conditions, each individual cytosol sample was first screened for residual AP and its primary metabolite oxypurinol. Because of the complexity of the sample matrix, contaminate peaks were observed. This was particularly an issue for oxypurinol because contaminate peaks with a similar retention time to the analyte were seen for some samples. To overcome this and ensure the validity of the results, each sample was spiked with a known concentration of heavy isotope labeled oxypurinol (oxypurinol-^{13}C^{15}N$_2$). Supplemental Figure 1 shows the peaks observed for oxypurinol and oxypurinol-^{13}C^{15}N$_2$ as well as typical contaminate peaks. For the determination of oxypurinol in each sample, it was ensured that the peak retention time matched exactly with the heavy isotope labeled standard. The method was further

TABLE 1
Concentration measurements for residual AP and oxypurinol in individual liver cytosol preparations

Individual livers were harvested in three different ways: full hepatectomy without an AP-containing perfusion solution (perfused w/o AP), full hepatectomy with an AP-containing perfusion solution (perfused w/ AP), and partial hepatectomy (resected). Pooled HLC purchased from a commercial source (commercial) was also tested. The method detection limit for AP and oxypurinol are stated in *Materials and Methods*. Values reflect the mean ± standard deviation for duplicate determinations.

Liver Number	Perfused w/o AP					Perfused w/ AP						Resected									Commercial
	103	104	109	111	113	121	125	130	139	146	344	913	932	947	955	962	963	964	965	967	
Residual [AP] (μM)	N.D.	N.D.	N.D.	N.D.	N.D.	11 ± 1.5	N.D.	3.5 ± 0.78	3.2 ± 0.34	N.D.	1.1 ± 0.08	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
Residual [OP] (μM)	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	2.5 ± 0.56	35 ± 5.8	32 ± 4.4	39 ± 4.7	19 ± 1.1	N/D	N/D	0.66 ± 0.029	N/D	N.D.	N.D.	N.D.	N.D.	N.D.	51 ± 0.61

N.D., no analyte detected

validated by generating a quality control curve for both analytes in which a known amount of AP and oxypurinol was added into a blank cytosol matrix (Supplemental Fig. 2).

Table 1 shows the amount of AP and oxypurinol found in each sample of HLC. As indicated on the table, the leftmost group originated from donor livers that were harvested via a full hepatectomy and perfused with a solution that did not contain AP (group 1). The center group of livers were harvested via full hepatectomy and perfused with UW solution containing 1 mM AP (group 2). The group of liver samples on the right was obtained from partial hepatectomies (resections) (group 3). For the livers in group 1, no AP or oxypurinol was detected. Two of the five livers from group 2 contained a varied amount of residual AP, whereas all 5 had detectable amounts of oxypurinol. Of the livers in group 3, eight out of ten showed no trace of residual AP or oxypurinol. Interestingly, two livers from the resected group (344 and 947) did show a residual amount of oxypurinol. When the origins of these two liver samples were thoroughly investigated, it was found that they were flushed with UW solution and shipped on ice prior to being frozen. This exposure to UW solution clearly explains why oxypurinol was detected in these two samples.

It is worth noting that oxypurinol concentrations were found at much higher levels than AP itself. Also, AP was not observed in all livers that were perfused with UW solution, whereas in all cases oxypurinol was observed. This is likely a result of metabolism that is occurring throughout the processing time of the cytosol prior to being frozen. Because oxypurinol is a product of AP metabolism, the formation of oxypurinol is dependent on the time in which the liver was exposed to AP. Therefore, variable handling time may explain the large variation in oxypurinol concentration observed between AP dosed livers.

Once the presence or absence of AP and oxypurinol in certain liver cytosol batches was established, the possible effect this had on XO enzymatic activity was evaluated. Two compounds were chosen as selective XO substrates (Scheme 1). The first, 6-mercaptopurine, is metabolized in two steps to 6-thiouricacid (Kalra et al., 2007; Rashidi et al., 2007). The second probe, 6-nitroquinazolinone, is a known substrate for XO (Skibo et al., 1987) but not for AO (Alfaro et al., 2009). Figure 1 shows the results of activity screening for human livers that were procured in three different ways, again with groups 1–3. From these results, it is clear that the presence of AP in the administered perfusion solution has a marked impact on XO activity. In every case when livers were perfused with an AP-containing solution prior to harvest, XO activity was not observed. In contrast, XO activity was observed in every case where the liver was perfused with a solution that did not contain AP. Not surprisingly, XO activity was also observed in all of the resected livers except the two that had residual amounts of AP and oxypurinol present. Without exception, the presence of oxypurinol in the cytosol was an indicator of an absence of XO activity. Interestingly, the lack of XO activity was not dependent


Fig. 1. Measured enzymatic activity for individual liver samples for two XO probe substrates (top) and one AO substrate (bottom). Livers are grouped into three different harvesting conditions: full hepatectomy using a perfusion solution without allopurinol (left group), full hepatectomy using a perfusion solution containing 1 mM allopurinol (center group), and partial hepatectomy/resection (right group). The activity units denote the amount of product formed (nmol or pmol) per minute per mg of cytosolic protein. Asterisks indicate samples that showed no XO activity for either probe substrate. Asterisks also indicate samples in which residual oxypurinol was detected. The method detection limit for XO metabolites is stated in *Materials and Methods*.

at all on the concentration of AP or oxypurinol. This is likely because AP and oxypurinol are also a known time-dependent inactivators of XO (Elion, 1966; Massey et al., 1970), and thus exposure time during liver processing may eradicate all XO activity even at relatively low concentrations (Scheme 2).

The impact of liver harvesting conditions on AO activity was also examined. By use of the probe substrate DACA (Schofield et al., 2000; Barr and Jones, 2013), each liver was screened for enzymatic activity. AO activity was observed for livers in all three groups, and the presence of AP and oxypurinol appeared to have no observable effect (Fig. 1). To confirm this, an IC_{50} inhibition assay was performed with AP and oxypurinol (Supplemental Fig. 3). For both compounds, the IC_{50} exceeded 1 mM, an amount that is far greater than any residual amount of AP or oxypurinol in the cytosol. From these results, it is clear that AO activity is not affected by AP or oxypurinol.

Similar to the cases of individual donors that were perfused with AP, commercial pooled HLC did contain residual oxypurinol (Table 1), and, not surprisingly, XO activity was not observed (data not shown). As discussed in the introductory section, accurate knowledge of XO activity toward new chemical entities is largely dependent on selective chemical inhibition experiments using commercial HLC as the enzyme source. Adding AP to cytosol that is already devoid of any XO activity would obviously have no effect, and thus the experimenter may erroneously draw the conclusion that XO has no role in metabolism of the tested compound. Therefore, it is certainly possible that some compounds may have been overlooked as potential XO substrates using the standard in vitro selective chemical inhibition approaches. In the future, it is recommended that batches of cytosol be screened for AP and oxypurinol prior to testing for XO activity. Also, testing each batch for XO activity using a known active substrate such as 6-mercaptopurine would be advisable. Because of the variability in liver sources, it is possible that variation in AP and oxypurinol concentrations as well as XO activity would be observed between different cytosol vendors and possibly even within different batches from the same vendor. In addition, it seems likely that the presence of AP during liver harvest would also impact XO activity in other in vitro systems, including liver S9 and hepatocytes.

In conclusion, three groups of individual donor livers, procured in different ways, were examined for residual oxypurinol and AP concentration and presence of XO and AO enzymatic activity. The presence of residual AP (some) and oxypurinol (all) was observed in human liver cytosol preparations that had been perfused with UW solution. In every case where oxypurinol was detected, XO activity was not observed. In contrast, the presence of AP and oxypurinol did not appear to impact AO activity. This was supported by the fact that AP and oxypurinol inhibited AO activity, with IC_{50} values that exceeded 1 mM. Commercial pooled HLC also contained residual oxypurinol and did not show any XO activity. In the future, it is recommended that each HLC batch is screened for oxypurinol and/or XO activity prior to testing the metabolism of a new chemical entity.

Authorship Contributions

Participated in research design: Barr, Choughule, Zientek, Strom, Schuetz, Thummel, Jones.

Conducted experiments: Barr, Choughule, Nepal, Wong, Chaudhry, Joswig-Jones.

Performed data analysis: Barr, Choughule, Jones, Nepal.

Wrote or contributed to the writing of the manuscript: Barr, Zientek, Schuetz, Thummel, Jones.

References

Alfaro JF and Jones JP (2008) Studies on the mechanism of aldehyde oxidase and xanthine oxidase. *J Org Chem* **73**:9469–9472.

Alfaro JF, Joswig-Jones CA, Ouyang W, Nichols J, Crouch GJ, and Jones JP (2009) Purification and mechanism of human aldehyde oxidase expressed in Escherichia coli. *Drug Metab Dispos* **37**:2393–2398.

Barr JT and Jones JP (2013) Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase. *Drug Metab Dispos* **41**:24–29.

Barr JT, Jones JP, Joswig-Jones CA, and Rock DA (2013) Absolute quantification of aldehyde oxidase protein in human liver using liquid chromatography-tandem mass spectrometry. *Mol Pharm* **10**:3842–3849.

Elion GB (1966) Enzymatic and metabolic studies with allopurinol. *Ann Rheum Dis* **25**(6, Suppl) 608–614.

Elion GB, Kovensky A, and Hitchings GH (1966) Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. *Biochem Pharmacol* **15**:863–880.

Feng L, Zhao N, Yao X, Sun X, Du L, Diao X, Li S, and Li Y (2007) Histidine-tryptophan-ketoglutarate solution vs. University of Wisconsin solution for liver transplantation: a systematic review. *Liver Transpl* **13**:1125–1136.

Garattini E, Mendel R, Romão MJ, Wright R, and Terao M (2003) Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. *Biochem J* **372**:15–32.

Garattini E and Terao M (2012) The role of aldehyde oxidase in drug metabolism. *Expert Opin Drug Metab Toxicol* **8**:487–503.

Hutzler JM, Obach RS, Dalvie D, and Zientek MA (2013) Strategies for a comprehensive understanding of metabolism by aldehyde oxidase. *Expert Opin Drug Metab Toxicol* **9**: 153–168.

Janssen H, Janssen PH, and Broelsch CE (2004) UW is superior to Celsior and HTK in the protection of human liver endothelial cells against preservation injury. *Liver Transpl* **10**: 1514–1523.

Kalra S, Jena G, Tikoo K, and Mukhopadhyay AK (2007) Preferential inhibition of xanthine oxidase by 2-amino-6-hydroxy-8-mercaptopurine and 2-amino-6-purine thiol. *BMC Biochem* **8**:8.

Massey V, Komai H, Palmer G, and Elion GB (1970) On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. *J Biol Chem* **245**:2837–2844.

Mendes-Braz M, Elias-Miró M, Jiménez-Castro MB, Casillas-Ramírez A, Ramalho FS, and Peralta C (2012) The current state of knowledge of hepatic ischemia-reperfusion injury based on its study in experimental models. *J Biomed Biotechnol* **2012**:298657.

Mühlbacher F, Langer F, and Mittermayer C (1999) Preservation solutions for transplantation. *Transplant Proc* **31**:2069–2070.

Panoutsopoulos GI, Kouretas D, and Beedham C (2004) Contribution of aldehyde oxidase, xanthine oxidase, and aldehyde dehydrogenase on the oxidation of aromatic aldehydes. *Chem Res Toxicol* **17**:1368–1376.

Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, and Tran TD (2010) Aldehyde oxidase: an enzyme of emerging importance in drug discovery. *J Med Chem* **53**:8441–8460.

Rashidi MR, Beedham C, Smith JS, and Davaran S (2007) In vitro study of 6-mercaptopurine oxidation catalysed by aldehyde oxidase and xanthine oxidase. *Drug Metab Pharmacokinet* **22**: 299–306.

Schofield PC, Robertson IG, and Paxton JW (2000) Inter-species variation in the metabolism and inhibition of N-[(2′-dimethylamino)ethyl]acridine-4-carboxamide (DACA) by aldehyde oxidase. *Biochem Pharmacol* **59**:161–165.

Skibo EB, Gilchrist JH, and Lee CH (1987) Electronic probes of the mechanism of substrate oxidation by buttermilk xanthine oxidase: role of the active-site nucleophile in oxidation. *Biochemistry* **26**:3032–3037.

Strelevitz TJ, Orozco CC, and Obach RS (2012) Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance. *Drug Metab Dispos* **40**:1441–1448.

Watson CJ and Dark JH (2012) Organ transplantation: historical perspective and current practice. *Br J Anaesth* **108** (Suppl 1):i29–i42.

Address correspondence to: J. P. Jones, Department of Chemistry, Washington State University, P.O. Box 644630, Pullman, Washington 99164-4630. E-mail: jpj@wsu.edu